Literature DB >> 8855310

Identification of the endothelial cell binding site for factor IX.

W F Cheung1, J van den Born, K Kühn, L Kjellén, B G Hudson, D W Stafford.   

Abstract

We previously demonstrated that the primary region of factor IX and IXa responsible for saturable specific binding to bovine aortic endothelial cells resides in residues 3-11 at the amino terminus of factor IX. We also demonstrated that mutations of lysine to alanine at residue 5, factor IX K5A, or valine to lysine at residue 10, factor IX V10K, resulted in a molecule unable to bind to endothelial cells. Moreover, a mutation with lysine to arginine at residue 5, factor IX K5R, resulted in a factor IX molecule with increased affinity for the endothelial cell binding site. In this paper we report that collagen IV is a strong candidate for the factor IX binding site on endothelial cells. Factor IX and factor IX K5R compete with 125I-labeled factor IX for binding to tetrameric collagen IV immobilized on microtiter plates, while factor X, factor VII, and factor IX K5A or V10K fail to compete. The Kd for wild-type factor IX binding to collagen IV in the presence of heparin was 6.8 +/- 2 nM, and the Kd for factor IX K5R was 1.1 +/- 0.2 nM, which agrees well with our previously published Kd values of 7.4 and 2.4 nM for binding of the same proteins to endothelial cells. Our working assumption is that we have identified the endothelial cell binding site and that it is collagen IV. Its physiological relevance remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855310      PMCID: PMC38285          DOI: 10.1073/pnas.93.20.11068

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X.

Authors:  D M Stern; P P Nawroth; W Kisiel; G Vehar; C T Esmon
Journal:  J Biol Chem       Date:  1985-06-10       Impact factor: 5.157

2.  A network model for the organization of type IV collagen molecules in basement membranes.

Authors:  R Timpl; H Wiedemann; V van Delden; H Furthmayr; K Kühn
Journal:  Eur J Biochem       Date:  1981-11

3.  Binding of factors IX and IXa to cultured vascular endothelial cells.

Authors:  D M Stern; M Drillings; H L Nossel; A Hurlet-Jensen; K S LaGamma; J Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

4.  Nature of the collagenous protein in a tumor basement membrane.

Authors:  R Timpl; G R Martin; P Bruckner; G Wick; H Wiedemann
Journal:  Eur J Biochem       Date:  1978-03

5.  7-S collagen: characterization of an unusual basement membrane structure.

Authors:  J Risteli; H P Bächinger; J Engel; H Furthmayr; R Timpl
Journal:  Eur J Biochem       Date:  1980

6.  Recombinant leech antiplatelet protein specifically blocks platelet deposition on collagen surfaces under flow conditions.

Authors:  G H van Zanten; T M Connolly; M E Schiphorst; S de Graaf; P J Slootweg; J J Sixma
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-09       Impact factor: 8.311

7.  Binding of coagulation factors IX and X to the endothelial cell surface.

Authors:  R L Heimark; S M Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1983-03-16       Impact factor: 3.575

8.  Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen.

Authors:  S A Santoro
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

9.  Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading.

Authors:  H K Nieuwenhuis; K S Sakariassen; W P Houdijk; P F Nievelstein; J J Sixma
Journal:  Blood       Date:  1986-09       Impact factor: 22.113

10.  Isolation of the pericellular matrix of human fibroblast cultures.

Authors:  K Hedman; M Kurkinen; K Alitalo; A Vaheri; S Johansson; M Höök
Journal:  J Cell Biol       Date:  1979-04       Impact factor: 10.539

View more
  24 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

3.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

Review 4.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.

Authors:  J Des Parkin; James D San Antonio; Vadim Pedchenko; Billy Hudson; Shane T Jensen; Judy Savige
Journal:  Hum Mutat       Date:  2011-02       Impact factor: 4.878

Review 5.  Secondary prophylaxis with factor IX concentrates: continuous infusion.

Authors:  Massimo Morfini
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 6.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

7.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

8.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

Review 9.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

10.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.